Dr. Schwartzberg on Emerging Biomarkers in NSCLC

Lee S. Schwartzberg, MD
Published: Thursday, Mar 08, 2018



Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).

HER2 amplification is commonly seen in breast cancer, but HER2 mutations occur in a wide variety of tumors. HER2 mutations are found in 1% to 2% of NSCLC. Early data suggest that agents that target HER2 may be useful in this population.

MET alterations are also potentially targetable. There are a variety of others that are coming out as well. In the squamous cell group, FGFR alterations, either amplification or mutation are very commonly seen. Although there is no FDA-approved agent for that alteration, a large number of clinical trials are investigating the use of FGFR inhibitors in that population.
 


Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).

HER2 amplification is commonly seen in breast cancer, but HER2 mutations occur in a wide variety of tumors. HER2 mutations are found in 1% to 2% of NSCLC. Early data suggest that agents that target HER2 may be useful in this population.

MET alterations are also potentially targetable. There are a variety of others that are coming out as well. In the squamous cell group, FGFR alterations, either amplification or mutation are very commonly seen. Although there is no FDA-approved agent for that alteration, a large number of clinical trials are investigating the use of FGFR inhibitors in that population.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x